
A decision-analytical model shows that everolimus has a favorable budget impact when introduced into the treatment algorithm for metastatic renal cell carcinoma.

A decision-analytical model shows that everolimus has a favorable budget impact when introduced into the treatment algorithm for metastatic renal cell carcinoma.

Saxagliptin, in combination with metformin, provides a durable, well-tolerated, and cost-effective treatment option for patients with type 2 diabetes mellitus, from a US payer perspective.

Published: February 11th 2012 | Updated:

Published: November 13th 2012 | Updated: